Tag:

Foundation Medicine

Latest Headlines

Latest Headlines

Genomic Health readies for liquid biopsy test launch; Foundation Medicine jumps on liquid biopsy bandwagon amid positive Q4 numbers

In this week's Dx Digest, Genomic Health announced plans to roll out its liquid biopsy test in 2016. Foundation Medicine revealed positive Q4 numbers and talked up its liquid biopsy ambitions. And Qiagen expanded its companion diagnostics prowess through a deal with Array BioPharma.

Roche leads $175M investment in oncology software player Flatiron

Roche has led a $175 million investment in Flatiron Health, the oncology software player set up by a pair of former Google employees in 2012. The deal, which also sees Roche sign up to use Flatiron's services, continues the Big Pharma's drive to connect its R&D teams to a broader pool of data.

Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss

In this week's Dx Digest, Illumina unveiled a $250 million share repurchase program, Quest Diagnostics inked a deal with lab data analytics firm Medivo to use its data sets to help match patients to new drug therapies, and Foundation Medicine reported a beat on revenues for the third quarter, even though it missed the Street's expectations on earnings.

Foundation Medicine unveils new NGS cancer tool amid sluggish reimbursement

Foundation Medicine is rolling out a cancer genomics software system for next-generation sequencing (NGS) tests, building out its offerings amid an increasingly stringent reimbursement environment.

Foundation Medicine unveils new NGS cancer tool amid sluggish reimbursement

Foundation Medicine is rolling out a cancer genomics software system for next-generation sequencing (NGS) tests, building out its offerings amid an increasingly stringent reimbursement environment.

Foundation Medicine trips in Q2 with sluggish test reimbursement

Foundation Medicine has been riding a wave of good fortune this year, striking a deal with diagnostics heavyweight Roche to bolster its industry footprint and accelerate product development. But the company hit a rough patch in Q2, with slower-than-expected reimbursement for its tests and results that missed the Street's expectations.

Foundation Medicine trips in Q2 with sluggish test reimbursement

Foundation Medicine has been riding a wave of good fortune this year, striking a deal with diagnostics heavyweight Roche to bolster its industry footprint and accelerate product development. But the company hit a rough patch in Q2, with slower-than-expected reimbursement for its tests and results that missed the Street's expectations.

Foundation Medicine teams with IMS on precision medicine service

Foundation Medicine and IMS Health have teamed up to offer a precision medicine service. The alliance brings together Foundation Medicine's cancer genomics database and IMS' real-world evidence platform, a combination the partners think can enable the effective use of more targeted therapies.

Foundation Medicine teams up with IMS Health for cancer precision medicine project

Foundation Medicine is teaming up with healthcare technology firm IMS Health to develop a new cancer diagnostics tool, deepening the company's dive into cancer R&D a few months after it finalized its $1.2 billion deal with Roche.

Fresh off $250M investment from Roche, Foundation Medicine testing volume up 67%

Foundation Medicine provided additional detail about Roche's multimillion-dollar investment in the cancer-focused molecular diagnostic company during its Q1 2015 earnings call.
'